Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12160-12169

  Leveille, Simon ^a,b   Goulet, Marie Line ^a   Lichty, Brian D ^c   Hiscott, John ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; RECOMBINANT FMS LIKE TYROSINE KINASE 3 LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR ANTIGEN PRESENTATION; TUMOR ASSOCIATED DENDRITIC CELL; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE THERAPY; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; SURVIVAL RATE; T-LYMPHOCYTES; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALIA; VESICULAR STOMATITIS VIRUS;

EID: 81255164999     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05703-11     Document Type: Article

References (37)

1. Ahmed, M., K. L. Brzoza, and E. M. Hiltbold. 2006. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J. Virol. 80:2194-2205.
2. Ahmed, M., et al. 2009. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J. Virol. 83:2962-2975.
3. Barber, G. N. 2005. VSV-tumor selective replication and protein translation. Oncogene 24:7710-7719.
4. Bell, J. 2010. Oncolytic viruses: an approved product on the horizon? Mol. Ther. 18:233-234.
5. Boudreau, J. E., et al. 2009. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 17:1465-1472.
6. Boudreau, J. E., et al. 2011. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 71:2497-2506.
7. Breitbach, C. J., et al. 2011. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19:886-894.
8. Breitbach, C. J., et al. 2007. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15:1686-1693.
9. Bridle, B. W., et al. 2009. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. 17:1814-1821.
10. Bridle, B. W., et al. 2010. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18:1430-1439.
11. Ciavarra, R. P., et al. 2000. Antigen processing of vesicular stomatitis virus in situ. Interdigitating dendritic cells present viral antigens independent of marginal dendritic cells but fail to prime CD4(+) and CD8(+) T cells. Immunology 101:512-520.
12. Ciavarra, R. P., A. Stephens, S. Nagy, M. Sekellick, and C. Steel. 2006. Evaluation of immunological paradigms in a virus model: are dendritic cells critical for antiviral immunity and viral clearance? J. Immunol. 177:492-500.
13. Ciavarra, R. P., et al. 2005. Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon. Virology 342:177-189.
14. Degli-Esposti, M. A., and M. J. Smyth. 2005. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5:112-124.
15. Diaz, R. M., et al. 2007. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67:2840-2848.
16. Fernandez, N. C., et al. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405-411.
17. Galivo, F., et al. 2010. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum. Gene Ther. 21:439-450.
18. Galivo, F., et al. 2010. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 17:158-170.
19. Gottfried, E., M. Kreutz, and A. Mackensen. 2008. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 19:65-77.
20. Inaba, K., et al. 2009. Isolation of dendritic cells. Curr. Protoc. Immunol. 3:3.7.
21. Kottke, T., et al. 2011. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat. Med. 17:854-859.
22. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:4477-4481.
23. Leveille, S., S. Samuel, M. L. Goulet, and J. Hiscott. 2011. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther. 18:435-443.
24. Lichty, B. D., A. T. Power, D. F. Stojdl, and J. C. Bell. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216.
25. Ludewig, B., et al. 2000. Induction of optimal anti-viral neutralizing B cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. Eur. J. Immunol. 30:185-196.
26. Maraskovsky, E., et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-1962.
27. Mende, I., and E. G. Engleman. 2005. Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann. N. Y. Acad. Sci. 1058:96-104.
28. Prestwich, R. J., et al. 2009. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20:1119-1132.
29. Randolph, G. J., J. Ochando, and S. Partida-Sanchez. 2008. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26:293-316.
30. Rowan, K. 2010. Oncolytic viruses move forward in clinical trials. J. Natl. Cancer Inst. 102:590-595.
31. Shaw, S. G., A. A. Maung, R. J. Steptoe, A. W. Thomson, and N. L. Vujanovic. 1998. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J. Immunol. 161:2817-2824.
32. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449:419-426.
33. Stojdl, D. F., et al. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
34. Willmon, C., et al. 2011. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol. Ther. 19:140-149.
35. Willmon, C. L., et al. 2009. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 69:7713-7720.
36. Wongthida, P., et al. 2011. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 19:150-158.
37. Wongthida, P., et al. 11 April 2011. Activating systemic T cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. doi: 10.1089/hum.2010.216.